Find your people Clinical trials, cannabinoid science, and the evidence shaping policy.
The FSA has backed the first three high-purity CBD novel-food applications for ministerial approval. It is a regulatory milestone—not permission for medicinal claims or every CBD product on sale.
A controlled trial found that 800 mg of CBD reduced neuropathic pain after spinal-cord injury—but the average benefit was modest and the dose was far removed from retail CBD oil.
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
A new systematic review finds that pure CBD is not the main problem. Undeclared THC, inconsistent products and blunt testing policies are where the real risk sits.
From pain management to mental health, the clinical research pipeline for cannabinoid medicines is more active than ever. Here are the studies to watch.
Clinical research offers encouraging signals, but different conditions, doses and study designs make broad claims about CBD and anxiety premature.
THC-based medicines may help some people with chronic pain, but variable benefits, side effects and limited long-term data demand a measured reading.
Terpenes — the aromatic compounds in cannabis — are emerging as a key area of research with potential therapeutic applications.
FDA releases March 2026 draft guidance on hemp-derived CBD, proposing a 20 mg daily cap and strict labelling rules for a $4B+ market.